Literature DB >> 1370834

Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases.

P Huang1, D Farquhar, W Plunkett.   

Abstract

This study used DNA primer extension and sequencing gel analyses to evaluate the molecular action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate (D4TTP), in comparison with 3'-azido-2',3'-dideoxythymidine triphosphate (AZTTP), on DNA strand elongation by human immunodeficiency virus reverse transcriptases (HIV-RT) and human DNA polymerases alpha (pol alpha) and epsilon (pol epsilon) purified from T-lymphoblastoid CEM cells. D4TTP was preferentially incorporated into the T sites of the elongating DNA strand by HIV-RT and terminated DNA synthesis at the incorporation sites. The DNA chain termination activity of D4TTP was equipotent to that of AZTTP. In contrast, D4TTP was a poor substrate for pol alpha and pol epsilon. The analogue was incorporated into DNA by the human enzymes about 10,000- to 20,000-fold less efficiently than by HIV-RT, whereas the incorporation of AZTTP by pol alpha and pol epsilon was not detectable by the DNA primer extension assay. Pol epsilon, an enzyme with 3'----5'-exonuclease activity, was unable to remove the incorporated 2',3'-didehydro-2',3'-dideoxythymidine monophosphate (D4TMP) from the 3'-end of the DNA strand, whereas 3'-azido-2',3'-dideoxythymidine monophosphate was excised from DNA by pol epsilon at about 20% of the rate for normal deoxynucleotide excision. The preferential incorporation of D4TTP by HIV-RT appears to be a molecular basis for the selective anti-HIV activity of D4T, whereas the inability of pol epsilon to remove D4TMP from DNA may be related to the cytotoxicity of this compound.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370834

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.486


  11 in total

Review 1.  Stavudine once daily.

Authors:  Susan M Cheer; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Stavudine: an update of its use in the treatment of HIV infection.

Authors:  M Hurst; S Noble
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Radioimmunoassay for quantitation of 2',3'-didehydro-3'-deoxythymidine (D4T) in human plasma.

Authors:  X J Zhou; H Chakboub; B Ferrua; J Moravek; R Guedj; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 4.  Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.

Authors:  A P Lea; D Faulds
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 5.  Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

Authors:  Nila Bhana; Douglas Ormrod; Caroline M Perry; David P Figgitt
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 6.  The mitochondrial DNA polymerase in health and disease.

Authors:  William C Copeland
Journal:  Subcell Biochem       Date:  2010

7.  4'-Acylated thymidine 5'-triphosphates: a tool to increase selectivity towards HIV-1 reverse transcriptase.

Authors:  A Marx; M Amacker; M Stucki; U Hübscher; T A Bickle; B Giese
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

8.  2-Chloro-2'-deoxyadenosine monophosphate residues in DNA enhance susceptibility to 3'-->5' exonucleases.

Authors:  P Hentosh; P Grippo
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

9.  Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathy.

Authors:  James J Kohler; Seyed H Hosseini; William Lewis
Journal:  Chem Res Toxicol       Date:  2008-04-05       Impact factor: 3.739

10.  Ionotropically Gelled Novel Hydrogel Beads: Preparation, Characterization and In vitro Evaluation.

Authors:  J S Patil; M V Kamalapur; S C Marapur; S S Shiralshetti
Journal:  Indian J Pharm Sci       Date:  2011-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.